CureVac B.V.

General Information


We are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our current product portfolio includes CV8102, a cancer drug in a Phase 1 clinical trial to treat four types of solid tumors, and CV7202, a potential rabies vaccine in a Phase 1 clinical trial, and a potential COVID-19 (coronavirus or SARS-CoV-2) vaccine, for which we initiated a Phase 1 clinical trial in healthy volunteers in June 2020, with results expected in the fourth quarter of 2020.

Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are the pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins.




Employees: 484
Founded: 2000
Contact Information
Address Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany
Phone Number +49 7071 9883 0
Web Address
View Prospectus: CureVac B.V.
Financial Information
Market Cap $3167.4mil
Revenues $17.4 mil (last 12 months)
Net Income $-102.4 mil (last 12 months)
IPO Profile
Symbol CVAC
Exchange NASDAQ
Shares (millions): 13.3
Price range $16.00 - $16.00
Est. $ Volume $213.3 mil
Manager / Joint Managers BofA Securities/ Jefferies/ Credit Suisse
CO-Managers Berenberg/ Kempen & Co.
Expected To Trade: 8/14/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change